Skip to content

Disc Medicine IRON Additional Paid-In Capital

Additional Paid-In Capital at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$46.37B+0.8%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$1.12B+7.8%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$2.57B+2.6%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$2.9B+3.7%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$1.61B+5.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$2.11B+9.0%

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's additional paid-in capital?
Disc Medicine (IRON) reported additional paid-in capital of $1.26B in Q1 2026.
How has Disc Medicine's additional paid-in capital changed year-over-year?
Disc Medicine's additional paid-in capital increased by 27.3% year-over-year, from $991.91M to $1.26B.
What is the long-term trend for Disc Medicine's additional paid-in capital?
Over 5 years (2020 to 2025), Disc Medicine's additional paid-in capital has grown at a 68.9% compound annual growth rate (CAGR), from $90.96M to $1.25B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.